4/A: Oncology Institute Director Brad Hively Amends Form 4 to Correctly Report Securities Acquisition
SEC Form 4/A
Brad Hively, a director at Oncology Institute, files an amended Form 4 to correct the number of shares and warrants acquired in a private placement.
Summary
- Brad Hively, a director of Oncology Institute, Inc., filed an amendment to his Form 4 to correct the number of shares of Common Stock and Common Warrants acquired in a private placement transaction.
- The original Form 4 was filed on March 28, 2025, and this amendment corrects the amount of securities beneficially owned following the reported transaction.
- On March 26, 2025, Hively acquired 45,280 shares of Common Stock at $1.0417 per share and 22,640 Common Warrants at $0.1250 per warrant.
- These securities were purchased in a private placement directly from the company, as per a Securities Purchase Agreement dated March 24, 2025.
- Each Private Placement Unit consisted of two shares of Common Stock and one Common Warrant, priced at $2.2084 per unit.
- Hively is restricted from exercising the Common Warrants if it would result in him beneficially owning more than 4.99% of the company's outstanding Common Stock.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, but the director's increased stake could be seen as a positive signal. The amendment itself is neutral.
Risks
- The warrant exercise limitation at 4.99% ownership could restrict Hively's ability to fully capitalize on the warrants if the stock price increases significantly.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's securities, ensuring transparency and compliance with SEC regulations.
Related Party Transactions
- The private placement transaction between Oncology Institute and its director, Brad Hively, constitutes a related party transaction.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholders due to the director's increased investment, signaling confidence in the company.
- The private placement provides the company with additional capital.
Key Dates
| Date | Description |
|---|---|
| 03/24/2025 | Date of the Securities Purchase Agreement |
| 03/26/2025 | Date of the transaction (acquisition of shares and warrants) |
| 03/26/2030 | Expiration date of the Common Warrants |
| 03/28/2025 | Date of original Form 4 filing |
| 04/28/2025 | Date of amended Form 4 filing |
Keywords
Form 4, Amendment, Private Placement, Common Stock, Common Warrant, Oncology Institute, Director, Hively
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.